Biodesix price target raised to $22 from $20 at Canaccord

Canaccord raised the firm’s price target on Biodesix (BDSX) to $22 from $20 and keeps a Buy rating on the shares. The firm said the price target increase is primarily driven by increased revenue assumptions and operating margin expansion in our 10-year DCF model.